Aktis Oncology (NASDAQ:AKTS) Trading Up 5.8% – Time to Buy?

Aktis Oncology (NASDAQ:AKTS)’s share price traded up 5.8% on Tuesday . The stock traded as high as $26.10 and last traded at $26.23. Approximately 34,422 shares were traded during trading, a decline of 89% from the average session volume of 304,971 shares. The stock had previously closed at $24.79.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on AKTS. Weiss Ratings downgraded Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, June 9th. William Blair initiated coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock. Raymond James Financial began coverage on shares of Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price objective for the company. Finally, HC Wainwright lifted their target price on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Aktis Oncology Trading Up 8.6%

The company’s 50 day moving average is $19.97.

Aktis Oncology (NASDAQ:AKTS) last posted its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The company had revenue of $1.87 million for the quarter. Analysts anticipate that Aktis Oncology will post -1.62 EPS for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.